PANACEABIO Stock Overview
A biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Panacea Biotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹448.15 |
| 52 Week High | ₹490.55 |
| 52 Week Low | ₹112.35 |
| Beta | 0.87 |
| 1 Month Change | 8.25% |
| 3 Month Change | 42.68% |
| 1 Year Change | 182.12% |
| 3 Year Change | 134.39% |
| 5 Year Change | 239.64% |
| Change since IPO | 651.93% |
Recent News & Updates
Recent updates
There's No Escaping Panacea Biotec Limited's (NSE:PANACEABIO) Muted Revenues Despite A 34% Share Price Rise
Nov 22
There's No Escaping Panacea Biotec Limited's (NSE:PANACEABIO) Muted Revenues Despite A 40% Share Price Rise
Oct 03Most Shareholders Will Probably Find That The Compensation For Panacea Biotec Limited's (NSE:PANACEABIO) CEO Is Reasonable
Sep 21Panacea Biotec Limited (NSE:PANACEABIO) Held Back By Insufficient Growth Even After Shares Climb 25%
Aug 19Does Panacea Biotec (NSE:PANACEABIO) Have A Healthy Balance Sheet?
Jun 05Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S
Apr 04Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All
Sep 23Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)
Jul 28How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?
Feb 14Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years
Jan 06Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?
Sep 17
If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today
Aug 03Shareholder Returns
| PANACEABIO | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -4.1% | -4.6% | -4.2% |
| 1Y | 182.1% | 40.8% | 19.1% |
Return vs Industry: PANACEABIO exceeded the Indian Biotechs industry which returned 40.8% over the past year.
Return vs Market: PANACEABIO exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| PANACEABIO volatility | |
|---|---|
| PANACEABIO Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: PANACEABIO's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: PANACEABIO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,936 | Rajesh Jain | www.panaceabiotec.com |
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands.
Panacea Biotec Limited Fundamentals Summary
| PANACEABIO fundamental statistics | |
|---|---|
| Market cap | ₹27.45b |
| Earnings (TTM) | -₹147.13m |
| Revenue (TTM) | ₹5.50b |
5.0x
P/S Ratio-186.6x
P/E RatioIs PANACEABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PANACEABIO income statement (TTM) | |
|---|---|
| Revenue | ₹5.50b |
| Cost of Revenue | ₹2.02b |
| Gross Profit | ₹3.48b |
| Other Expenses | ₹3.63b |
| Earnings | -₹147.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | 63.28% |
| Net Profit Margin | -2.68% |
| Debt/Equity Ratio | 2.6% |
How did PANACEABIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:37 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Panacea Biotec Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Amit Gupta | Batlivala & Karani Securities India Pvt. Ltd. |
| Arvind Bothra | BofA Global Research |